Many patients on long-term antihypertensive treatment consider follow-up visits unnecessary as long as their home blood pressure measurements are normal and drugs can be ordered by phone. Are follow-up visits really needed?
Should we prescribe low-dose acetylsalicylic acid (ASA) for all patients with stable coronary disease?
Should all patients after myocardial infarction receive an angiotensin-converting enzyme (ACE) inhibitor?
Is it currently recommended to measure the uric acid level in blood and reduce it pharmacologically as part of cardiovascular disease prevention?
How to adjust the level of exercise in a patient with heart failure?
Which patients after myocardial infarction (MI) qualify for cardiac rehabilitation? When should it be started and what should it involve?
Should antihypertensive treatment be introduced in young patients with a mildly elevated systolic or diastolic blood pressure?
In which patients should proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors be used in the secondary prevention of myocardial infarction (MI)?
Which patients with heart failure should undergo a thorough diagnosis of rare causes of heart failure such as myopathy or storage diseases?
Which invasive treatment strategy is preferred in ST-segment elevation myocardial infarction (STEMI): PCI of the infarct-related artery only or revascularization of all significant lesions?
English
Polski
Español
українська